Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.
Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate (ORR) for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.
The positive top-line results were reported from the phase 3 REFLECTIONS B3281006 study, a randomized, double-blind clinical trial evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-05280586 versus the EU-approved MabThera.
REFLECTIONS B3281006 had an estimated enrollment of 394 adult participants and began in September 2014. It is expected to be completed later in 2018. The primary endpoint, ORR, is defined according to the revised response criteria for malignant lymphoma (time frame, week 26). Secondary outcome measures include time to treatment failure, progression-free survival, complete remission rate, duration of response, overall survival, incidence of anti-drug antibodies, and safety associated with immune response.
“These results reinforce the potential of our proposed rituximab biosimilar in providing a safe and effective treatment option for patients,” said Amrit Ray, MD, global president, Pfizer Essential Health Research and Development. “We are delivering on our commitment to advancing high-quality medicines for the millions of patients with cancer around the world today and in the future,” added Ray.
Pfizer has also investigated the proposed biosimilar for inflammatory indications. An earlier phase 1 clinical trial of PF-05280586 demonstrated pharmacokinetic similarity to US-licensed Rituxan and MabThera in 220 patients with active rheumatoid arthritis (RA) with inadequate response to 1 or more anti—tumor necrosis factor (anti-TNF) therapies. The researchers reported comparable pharmacodynamic responses as well as safety and immunogenicity profiles.
Another clinical trial of PF-05280586 in 214 patients with RA who had an inadequate response to anti-TNF drugs found no clinically meaningful differences in Disease Activity Score in 28 Joints (DAS28) or American College of Rheumatology (ACR) improvement criteria between the proposed biosimilar and the 2 reference drugs.
The complete results of the REFLECTIONS B3281006 trial will be submitted for presentation at a future medical conference or publication in a summary format, according to Pfizer.
Pfizer has 7 distinct biosimilar molecules in mid- to late-stage development, with 3 of these in oncology, as well as several others in early-stage development.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.